Stock Taper
NRSN
NEUROSENSE THERAPEUTICS LTD.
NASDAQ
$0.42
▼ DOWN 4.22% (-0.02)

KEY STATISTICS

Market Cap$14.86 M
52w High$1.98
52w Low$0.25
Dividend Yield
Frequency
P/E-0.82
Volume95.02K
Shares Out.35.35M

COMPANY

LEADERSHIP

Alon Ben-Noon
CHIEF EXECUTIVE
Alon Ben-Noon

ABOUT

SECTOR
Healthcare
WENT PUBLIC
December 9, 2021
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
17

UPCOMING EARNINGS

DateSep 2, 2026
DayWednesday
Rev. Est.$514.10K
SEP
2
WED

PRICE

$0.42 ▼ DOWN 4.22% (−$0.02)
$0.42$0.43$0.44$0.459:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM0.42

About NeuroSense Therapeutics Ltd.

https://www.neurosense-tx.com ↗

NeuroSense Therapeutics Ltd., a clinical-stage biotech in Herzliya, Israel, develops treatments for neurodegenerative diseases, with lead product PrimeC in Phase IIa for ALS and pipeline candidates for Parkinson’s and Alzheimer’s.

INDUSTRY

Biotechnology

A PRODUCT NEUROSENSE THERAPEUTICS LTD. IS KNOWN FOR

PrimeC
PrimeC

PrimeC is a clinical-stage, oral combination of FDA-approved ciprofloxacin and celecoxib, targeting ALS mechanisms, completed Phase 2b trials, and is NeuroSense's leading candidate for neurodegenerative disease treatment.

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity5
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score2

INSIDER TRADES

OFFICER: CHIEF EXECUTIVE OFFICER
Ben-Noon Alon
Purchase · 250.0K shares
2026-06-16
OFFICER: CHIEF FINANCIAL OFFICER
Eisenberg Or
Purchase · 250.0K shares
2026-06-16
OFFICER: CHIEF FINANCIAL OFFICER
Eisenberg Or
Purchase · 200.0K shares
2026-03-26
OFFICER: CHIEF FINANCIAL OFFICER
Eisenberg Or
· —
2026-03-18

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 1
1 GRADES IN THE LAST 12 MONTHS

SECTORS PEERS

PEERPRICE
NERV$4.84COMPARE
RLYB$16.81COMPARE
NRXS$6.00COMPARE
TAOX$3.89COMPARE
ENLV$1.35COMPARE
XCUR$1.29COMPARE
CVKD$1.54COMPARE
CLGN$0.36COMPARE